with 100 μg-dese and 300 μg-dose of CHP-MAGE-A4, respectively, in whom 14 patients in the 300 μg-dose were evaluable for immune responses. 18 had esophageal or head/neck squamous cell carcinoma. Among them,16 patients had refractory tumors, and 2 had no tumors after the first-line therapy. We evaluated the 16 patients with refractory esophageal or head/neck squamous cell carcinoma for survival analysis. The 14 patients were assessed for NY-ESO-1 antigen expression in the tumor tissues.
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